CY1123976T1 - Νεες ενωσεις με τριπλη θρομβολυτικη, αντιθρομβωτικη δραση και δραση δεσμευσης ελευθερων ριζων και συνθεση, νανομετρικη δομη και χρηση αυτων - Google Patents

Νεες ενωσεις με τριπλη θρομβολυτικη, αντιθρομβωτικη δραση και δραση δεσμευσης ελευθερων ριζων και συνθεση, νανομετρικη δομη και χρηση αυτων

Info

Publication number
CY1123976T1
CY1123976T1 CY20211100244T CY211100244T CY1123976T1 CY 1123976 T1 CY1123976 T1 CY 1123976T1 CY 20211100244 T CY20211100244 T CY 20211100244T CY 211100244 T CY211100244 T CY 211100244T CY 1123976 T1 CY1123976 T1 CY 1123976T1
Authority
CY
Cyprus
Prior art keywords
triple
free radical
composition
thrombolytic
compound
Prior art date
Application number
CY20211100244T
Other languages
English (en)
Inventor
Shiqi Peng
Jianhui Wu
Yuji Wang
Qiqi FENG
Ming Zhao
Original Assignee
Shanghai Lumosa Therapeutics Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Lumosa Therapeutics Co., Ltd. filed Critical Shanghai Lumosa Therapeutics Co., Ltd.
Publication of CY1123976T1 publication Critical patent/CY1123976T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια ένωση, η οποία έχει ταυτόχρονα τριπλή θρομβολυτική, αντιθρομβωτική δράση και δράση δέσμευσης ελευθέρων ριζών, καθώς και τη μέθοδο παρασκευής, τη σύνθεση και τις εφαρμογές αυτής. Η ένωση αντιπροσωπεύεται από τον τύπο Ι, ο οποίος φαίνεται παρακάτω όπου οι ορισμοί των Τ, Q, R1 και R2 περιγράφονται στο παρόν. Η ένωση της παρούσας εφεύρεσης έχει ταυτόχρονα τριπλές λειτουργίες θρομβόλυσης, δέσμευσης ελευθέρων ριζών και στόχευσης θρόμβου/αντιθρομβώσεως. Η παρούσα εφεύρεση αναφέρεται επίσης σε μια φαρμακευτική σύνθεση, η οποία περιλαμβάνει την ένωση, και μια μέθοδο παρασκευής και μία νανομετρική δομή της ένωσης.
CY20211100244T 2013-06-05 2021-03-22 Νεες ενωσεις με τριπλη θρομβολυτικη, αντιθρομβωτικη δραση και δραση δεσμευσης ελευθερων ριζων και συνθεση, νανομετρικη δομη και χρηση αυτων CY1123976T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310225330 2013-06-05
PCT/CN2014/079098 WO2014194809A1 (zh) 2013-06-05 2014-06-03 具有溶栓、抗栓和自由基清除三重活性的新型化合物、其合成、纳米结构和应用

Publications (1)

Publication Number Publication Date
CY1123976T1 true CY1123976T1 (el) 2022-05-27

Family

ID=52007559

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100244T CY1123976T1 (el) 2013-06-05 2021-03-22 Νεες ενωσεις με τριπλη θρομβολυτικη, αντιθρομβωτικη δραση και δραση δεσμευσης ελευθερων ριζων και συνθεση, νανομετρικη δομη και χρηση αυτων

Country Status (24)

Country Link
US (5) US9890193B2 (el)
EP (1) EP3006454B1 (el)
JP (1) JP6510500B2 (el)
KR (1) KR102204781B1 (el)
CN (1) CN104231046B (el)
AU (1) AU2014277416B2 (el)
BR (1) BR112015027164B1 (el)
CA (1) CA2914004C (el)
CY (1) CY1123976T1 (el)
DK (1) DK3006454T3 (el)
ES (1) ES2847934T3 (el)
HR (1) HRP20210566T1 (el)
HU (1) HUE053351T2 (el)
LT (1) LT3006454T (el)
MX (1) MX362902B (el)
PH (1) PH12015502684B1 (el)
PL (1) PL3006454T3 (el)
PT (1) PT3006454T (el)
RS (1) RS61606B1 (el)
RU (1) RU2660901C2 (el)
SI (1) SI3006454T1 (el)
TW (1) TWI633889B (el)
WO (1) WO2014194809A1 (el)
ZA (1) ZA201507237B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106608902A (zh) * 2015-10-22 2017-05-03 彭莉 二羟基二甲基四氢异喹啉-3-甲酰-Lys(Lys),其合成,活性及应用
CN106608905B (zh) * 2015-10-22 2020-10-16 彭莉 四氢异喹啉-3-甲酰-k(grpak)rgdv,其合成,活性及应用
JP6663774B2 (ja) 2016-03-30 2020-03-13 東京エレクトロン株式会社 基板搬送方法及び基板処理システム
WO2021062003A1 (en) * 2019-09-25 2021-04-01 Lumosa Therapeutics Co., Ltd Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
EP4149563A1 (en) * 2020-05-15 2023-03-22 Synhelix Peptidic scaffolds, processes for manufacturing the same, and uses thereof as soluble supports
CA3212069A1 (en) 2021-03-22 2022-09-29 Jung-Chin Lin Dc009 for treating acute ischemic stroke
CN115403653A (zh) * 2022-05-19 2022-11-29 首都医科大学 D(+)-β-(3,4-二羟基苯基)-乳酰-Pro-Ala-Lys,其合成及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5222632B2 (el) * 1972-08-22 1977-06-18
ES2247298T3 (es) 2001-01-23 2006-03-01 Eli Lilly And Company Derivados de piperazina y piperidina como agonistas del receptor de melanocortina.
ATE342057T1 (de) 2002-01-23 2006-11-15 Lilly Co Eli Melanocortinrezeptoragonisten
US7629319B2 (en) * 2002-12-23 2009-12-08 Janssen Pharmaceutica N.V. Heteroaryl peptidomimetics as thrombin receptor antagonists
CN101190895B (zh) 2006-11-30 2010-05-26 首都医科大学 N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用
CN101190941B (zh) * 2006-11-30 2010-12-01 首都医科大学 具有溶血栓活性的多肽、其制备方法及应用
CN101200493B (zh) 2006-12-11 2011-11-09 首都医科大学 （3s）-n-（l-氨基酰）-1，2，3，4-四氢异喹啉-3-羧酸、其制备方法及应用
CN102241740B (zh) * 2008-01-30 2014-02-19 首都医科大学 具有溶血栓活性的化合物、其制备方法、其应用
CN101497651B (zh) * 2008-01-30 2012-06-27 首都医科大学 具有溶血栓活性的化合物、其制备方法、其应用
CN101899084B (zh) 2009-05-26 2012-09-05 首都医科大学 (3s)-1,2,3,4-四氢异喹啉-3-羧酸三肽缀合物及其制备方法和应用
CN102120727B (zh) 2010-01-07 2013-08-28 首都医科大学 N-[(3s)-n-氨基酰-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸及其合成方法和应用
CN102127097A (zh) 2010-01-15 2011-07-20 首都医科大学 N-（3s-1,2,3,4-四氢异喹啉-3-甲酰基）氨基酸铜络合物及其制备方法和应用
CN102477068B (zh) 2010-11-30 2013-07-24 首都医科大学 用于制备溶血栓药物的氨基酸衍生物及其制备方法和应用
HUE034857T2 (en) * 2011-10-14 2018-03-28 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds are inhibitors of factor XIA
CN103145797B (zh) 2011-12-07 2015-05-20 首都医科大学 [(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]-Lys修饰的RGD四肽,其合成和在医学中的应用
CN103450338B (zh) 2012-05-29 2016-08-24 首都医科大学 杂环羧酸修饰的胸腺五肽，其制备，抗肿瘤作用和应用
CN103450330B (zh) * 2012-06-01 2016-05-25 首都医科大学 二羟基四氢异喹啉-3-甲酰氨基酸、其合成、抗血栓作用和应用
CN102887941A (zh) * 2012-09-05 2013-01-23 永光制药有限公司 Pak/咪唑啉/rgd三元缀合物及其制备方法和用途
CN105884905A (zh) * 2012-09-05 2016-08-24 上海晟顺生物科技有限公司 同时具溶血栓、清除自由基和血栓靶向功能的新颖化合物及其制备方法和用途

Also Published As

Publication number Publication date
RU2660901C2 (ru) 2018-07-11
TW201521759A (zh) 2015-06-16
US10351594B2 (en) 2019-07-16
PH12015502684A1 (en) 2016-03-07
CN104231046B (zh) 2017-05-03
CN104231046A (zh) 2014-12-24
AU2014277416A1 (en) 2015-12-24
US9890193B2 (en) 2018-02-13
JP2016521696A (ja) 2016-07-25
DK3006454T3 (da) 2021-04-12
ES2847934T3 (es) 2021-08-04
WO2014194809A1 (zh) 2014-12-11
AU2014277416B2 (en) 2018-02-22
US20230312644A1 (en) 2023-10-05
EP3006454A1 (en) 2016-04-13
KR102204781B1 (ko) 2021-01-20
LT3006454T (lt) 2021-04-12
EP3006454A4 (en) 2016-11-30
HUE053351T2 (hu) 2021-06-28
PH12015502684B1 (en) 2016-03-07
TWI633889B (zh) 2018-09-01
PL3006454T3 (pl) 2021-06-28
KR20160016863A (ko) 2016-02-15
RU2015147247A (ru) 2017-05-05
EP3006454B1 (en) 2021-01-13
CA2914004A1 (en) 2014-12-11
RS61606B1 (sr) 2021-04-29
SI3006454T1 (sl) 2021-04-30
BR112015027164B1 (pt) 2023-03-21
ZA201507237B (en) 2019-11-27
JP6510500B2 (ja) 2019-05-08
MX2015015924A (es) 2016-04-06
US20200055895A1 (en) 2020-02-20
US20210355163A1 (en) 2021-11-18
MX362902B (es) 2019-02-22
US20160083423A1 (en) 2016-03-24
US20180134748A1 (en) 2018-05-17
CA2914004C (en) 2022-01-25
PT3006454T (pt) 2021-01-29
HRP20210566T1 (hr) 2021-06-25
BR112015027164A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
CY1123976T1 (el) Νεες ενωσεις με τριπλη θρομβολυτικη, αντιθρομβωτικη δραση και δραση δεσμευσης ελευθερων ριζων και συνθεση, νανομετρικη δομη και χρηση αυτων
CU24377B1 (es) Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
EA201890522A1 (ru) Способ получения противогрибковых соединений
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
EA201791584A1 (ru) Агрохимическая композиция
CY1120080T1 (el) Φαρμακευτικη συνθεση περιεχουσα εναν αναστολεα hdac και εναν κυκλοπολυσακχαριτη
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
CO6640320A2 (es) Composición de control de fitoenfermedades y metodo de control de fitoenfermedades
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201591632A1 (ru) Цитотоксические и антимитотические соединения и способы их применения
EA201691580A1 (ru) Шестнадцатичленное макролидное соединение и его применение
EA201690911A1 (ru) Соединения диметилбензойной кислоты
EA201590381A1 (ru) Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
EA201501111A1 (ru) Замещенные n-(тетразол-5-ил)- и n-(триазол-5-ил)арилкарбоксамидные соединения и их применение в качестве гербицидов
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
EA201591349A1 (ru) Способ получения вортиоксетина
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
EA201690894A1 (ru) Феноксиэтилы
PH12014502752A1 (en) Novel cyclic depsipeptide derivative and pest control agent compromising same
EA201600304A1 (ru) Применение замещенных дигидрооксиндолилсульфонамидов или их солей для повышения толерантности растений к стрессу
EA201590379A1 (ru) Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа